Shopping Cart
- Remove All
Your shopping cart is currently empty
Shepherdin 79-87 acetate is a peptidomimetic antagonist of the complex between Hsp90 and survivin, another key regulator of tumor cell viability.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $148 | In Stock | |
| 5 mg | $336 | In Stock | |
| 10 mg | $497 | In Stock | |
| 25 mg | $793 | In Stock | |
| 50 mg | $1,130 | In Stock | |
| 100 mg | $1,520 | In Stock |
| Description | Shepherdin 79-87 acetate is a peptidomimetic antagonist of the complex between Hsp90 and survivin, another key regulator of tumor cell viability. |
| In vitro | When added to prostate carcinoma (PC3, DU145) or HeLa cells, shepherdin caused concentration-dependent and complete loss of cell viability[1]. |
| In vivo | Shepherdin-RV (50 mg/kg, i.p., daily) nearly completely ablated tumor growth in immunocompromised mice prostating carcinoma PC3 cells. In a breast cancer xenograft model that employs MCF-7 cells adapted in vivo, injection of Shepherdin-RV resulted in exponentially growing tumors independently of estrogen supplementation, which was unaffected by saline administration. Shepherdin-RV (50 mg/kg i.p. daily) uniformly inhibited the growth of these more aggressive tumors (p = 0.01) throughout a 23-day or 11-day treatment regimen. Shepherdin treatment resulted in nearly complete loss of Akt levels in tumor cells and severely attenuated expression of survivin[1]. |
| Synonyms | Shepherdin 79-87 acetate (861224-28-4 free base) |
| Molecular Weight | 1009.14 |
| Formula | C43H68N12O14S |
| Smiles | CC(C[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N)CCCCN)=O)Cc1nc[nH]c1)=O)CO)=O)CO)=O)=O)CS)=O)C)=O)Cc2ccccc2)=O)C(O)=O)C.CC(O)=O |
| Sequence | Lys-His-Ser-Ser-Gly-Cys-Ala-Phe-Gly(tBu) |
| Sequence Short | KHSSGCAFX |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.